Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07649252 | A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan | completed | — | 82 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 17, 2026 |
| clinicaltrials |
| NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | completed | — | 1 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03136783 | New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy(SkinTher) | completed | N/A | 1 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04495257 | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | completed | Phase 1 | 26 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 | 273 | Genentech, Inc.INDUSTRY | 8 | Jun 8, 2026 | clinicaltrials |
| NCT03949153 | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis(CRIRIN) | completed | Phase 1 / Phase 2 | 19 | University Hospital, Strasbourg, FranceOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01009177 | Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC) | completed | Phase 2 | 80 | ActelionINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03771859 | A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed | completed | — | 152 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT05542342 | Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.(SITISVEAL) | completed | Phase 2 | 16 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02073123 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 131 | NewLink Genetics CorporationINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT02645149 | Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma(Match Mel) | completed | Phase 2 | 216 | Melanoma Institute AustraliaOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04305054 | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 14 | May 28, 2026 | clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03336606 | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04253080 | Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors(ENZYMELA) | completed | N/A | 127 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04640545 | A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | completed | Phase 1 | 79 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT02437227 | Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833(PanRAF) | completed | Phase 1 | 31 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04146064 | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | completed | — | 190 | University Health Network, TorontoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT04726319 | Family History App in Personalized Medicine(FHAMe) | completed | N/A | 627 | University of TorontoOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06463509 | Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma(TUPRO) | completed | — | 116 | Reinhard DummerOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06151847 | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | completed | Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05421988 | Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma | completed | N/A | 56 | Soul Medicine InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06919809 | Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery | completed | N/A | 16 | McGuire InstituteINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05187884 | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma(NADOM) | completed | Phase 2 | 15 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).(COMBI-AD) | completed | Phase 3 | 870 | Novartis PharmaceuticalsINDUSTRY | 25 | Apr 21, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03348891 | TNF in Melanoma Patients Treated With Immunotherapy(MELANFα) | completed | N/A | 60 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02816021 | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05105100 | Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma | completed | — | 25 | University of California, San FranciscoOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | completed | Early Phase 1 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06694571 | Sun Protection and Tanning Awareness in Rural Schools(STARS) | completed | N/A | 38 | University of UtahOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05628883 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05148325 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors | completed | Phase 1 | 28 | Bio-Thera SolutionsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06861647 | iSITE: Investigation of Somatic Alterations in Tumours of the Eye(iSITE) | completed | — | 58 | The Wellcome Sanger InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07506447 | The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma | completed | — | 68 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT01840007 | Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma | completed | Phase 2 | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02133222 | Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy(AMMAM) | completed | N/A | 22 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03293784 | TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma(TICIMEL) | completed | Phase 1 | 33 | Institut Claudius RegaudOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03620019 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | completed | Phase 3 | 256 | AmgenINDUSTRY | 22 | Mar 27, 2026 | clinicaltrials |
| NCT02360579 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma(LN-144) | completed | Phase 2 | 220 | Iovance Biotherapeutics, Inc.INDUSTRY | 8 | Mar 25, 2026 | clinicaltrials |
| NCT02723721 | Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face(PICAMEL) | completed | Phase 2 | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03276832 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | completed | Phase 2 | 378 | Immunocore LtdINDUSTRY | 14 | Mar 17, 2026 | clinicaltrials |
| NCT06221397 | AI-based Medical Device Validation for Early Melanoma Detection(LEGIT_MC_EVCDA) | completed | — | 105 | AI Labs Group S.LINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials